Vitiligo Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Vitiligo overview On the Web |
American Roentgen Ray Society Images of Vitiligo overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Vitiligo (IPA Template:IPA) or leukoderma is a chronic skin condition that causes loss of pigment, resulting in irregular pale patches of skin. The cause of vitiligo is complex, may be multifactorial, and is not fully understood. There is some evidence suggesting it is caused by a combination of auto-immune, genetic, and environmental factors. Vitiligo is the most common depigmenting disease with a worldwide incidence of 1%.
Human pigmentation diseases, such as vitiligo, have been described for over 3,000 years by different cultures around the world. Some famous texts, as the Eber Papyrus, Atharva Veda or even the Bible, provide a description of "white spotted-diseases" that could include cases of vitiligo. Celsus was the first to use the word "vitiligo" in the first century A.C. and Moriz Kaposi was one of the first to describe the histopathologic features of vitiligo.
Vitiligo can be classified in two clinical subtypes. One is segmented vitiligo, which affects only 1 segment of the body (face, arm or leg); and non-segmented vitiligo, involving more than 1 segment, such as both knees or both hands.
Non-segmental Vitiligo | Segmental Vitiligo | |
---|---|---|
Definition | Involves both sides of the body, most common type | Involves 1 segment of the body (face, arm or leg) |
Age | Later onset is more common than in childhood | More common in childhood |
Onset and progression | Progressive, with acute episodes | Rapid and stabilizes |
Hair involvement | In later stages | Early |
Association with other autoimmune conditions | Yes | No |
Common location | Areas prone to pressure or friction | Face |
Response to autologous grafting | Good response | Relapses |
Table adapted from N Engl J Med 2009;360:160-9[1], EDF Vitiligo Guidelines, A. Taieb et al. [2] and J Am Acad Dermatol Mazereeuw-Hautier et al [3] |
Vitiligo is caused by a loss of skin melanocytes. Although the exact mechanism is not known, at least in some cases, an autoimmune process may play a role. [4][5] The fact that vitiligo is more prevalent in patients with certain autoimmune disorders, such as Addison's disease, hyperthyroidism, alopecia areata and pernicious anemia supports this hypothesis,[6][7][8] but it should also be recognized that the majority of patients with vitiligo do not have any autoimmune disorder.
Vitiligo is caused by a loss of skin melanocytes. Although the exact mechanism is not known, at least in some cases, an autoimmune process may play a role. [4][5]
There are numerous conditions that cause hypopigmentation from which vitiligo must be differentiated, and the most common are pityriasis alba, postinflammatory hypopigmentation, tinea versicolor, halo nevus, tuberous sclerosis and albinism.
Vitiligo is the most common human pigmentation disorder, with a prevalence of 1,000/100,000 (1%) of the population. Males and females are equally affected. Half of patients are diagnosed before the age of 20.
Autoimmune diseases and a family history of vitiligo are considered risk factors for developing this condition. A patient that has a relative with vitiligo has an 18 fold increased risk of developing the disease and having an earlier onset of the disease.
The natural history of vitiligo is variable. Depigmentation may be stable or progressive and can cause even a total body depigmentation or remit spontaneously, although spontaneous remission is uncommon.
Vitiligo is an asymptomatic disease that commonly presents during the second decade of life, with a gradual depigmentation over time.[9][10]
Vitiligo is a chronic skin condition that causes loss of pigment, resulting in irregular pale patches of skin that may be distributed according to different patterns.
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
Vitiligo. Adapted from Dermatology Atlas[11]
There are no laboratory abnormalities in vitiligo disease. Consideration should be given to ordering laboratory studies to exclude the presence of other associated conditions such as pernicious anemia, Addison's disease and thyroid disease.
Although not performed routinely, since the diagnosis of vitiligo is often reached by a thorough history assessment and physical examination, a biopsy of the lesion may show microscopical changes undergoing on the hypopigmented region.
Potent topical corticosteroids (mometasone) and topical calcineurin inhibitors are first-line therapy to achieve repigmentation of vitiligo lesions. Phototherapy has been proven effective for the treatment of generalized vitiligo. Combined treatment with both topical calcineurin inhibitors plus phototherapy have proven more effective in achieving repigmentation in a shorter period of time than single treatments.
Support groups and organizations are available to help individuals learn more about vitiligo, understand treatment options, and find support from other individuals with vitiligo.
|month=
ignored (help)
|month=
ignored (help)
|month=
ignored (help)
|month=
ignored (help)